



Published in final edited form as:

*Expert Rev Neurother.* 2014 April ; 14(4): 353–355. doi:10.1586/14737175.2014.890893.

## What are exosomes and how can they be used in multiple sclerosis therapy?

**Aya D Pusic,**

Department of Neurology, The University of Chicago, Chicago, IL 60637, USA and Committee on Neurobiology, The University of Chicago, Chicago, IL 60637, USA

**Kae M Pusic,** and

Department of Neurology, The University of Chicago, Chicago, IL 60637, USA

**Richard P Kraig**

Department of Neurology, The University of Chicago, Chicago, IL 60637, USA and Committee on Neurobiology, The University of Chicago, Chicago, IL 60637, USA, Tel.: +1 773 702 0802, Fax: +1 773 702 5175

Richard P Kraig: rkraig@neurology.bsd.uchicago.edu

### Abstract

Current treatment options for multiple sclerosis are limited and consist of immunosuppressors or agents to prevent immune infiltration of the brain. These therapies have potentially harmful side effects and do little to promote myelin repair. Instead, we suggest using exosomes, naturally occurring small vesicles that exert influence through the delivery of mRNA, microRNA and protein. Dendritic cells can be cultured from bone marrow and stimulated to release exosomes. When administered to the brain, these exosomes significantly increase myelination and improve remyelination following injury by prompting preoligodendrocytes to differentiate into myelin producing cells. Additionally, they are non-toxic and can easily cross the blood-brain barrier and, thus, have great potential as a therapeutic.

### Keywords

environmental enrichment; exosomes; miRNA; multiple sclerosis; remyelination

---

© 2014 Informa UK Ltd

Correspondence to: Richard P Kraig, rkraig@neurology.bsd.uchicago.edu.

#### Financial & competing interests disclosure

This work was supported by the National Institutes of Health Common Fund, through the Office of Strategic Coordination/Office of the Director (1-UH2 TR000918) and core facilities funds from the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1 TR000430). The work was also supported by a Illinois Pilot grant from the National Multiple Sclerosis Society (IL-0009), the National Institute of Neurological Disorders and Stroke (NS-19108), the National Institute of Child Health and Human Disorders (5 PO1 HD 09402) and the White Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Multiple sclerosis is an inflammatory disease involving oligodendrocyte loss, demyelination and failure to remyelinate damaged brain areas. Oligodendrocytes produce CNS myelin, the insulation surrounding axons that is necessary for neuronal signaling, including that of learning, memory and cognition. Damage to oligodendrocytes and demyelination, loss of this insulation, can lead to severe neurological disability. Remyelination is a spontaneously occurring repair process mediated by recruitment of oligodendrocyte precursor cells to damaged areas, and their subsequent differentiation into mature oligodendrocytes that are capable of replacing lost myelin. Initially, multiple sclerosis patients follow a relapsing-remitting disease course, characterized by periods of partial recovery associated with incomplete remyelination [1]. However, over time this ability to repair declines and patients develop a secondary-progressive, steadily worsening disease course.

Current therapies for multiple sclerosis are largely directed at reducing demyelination via immune suppression, and often come with an array of harmful immune sequelae [2]. No existing therapies treat progressive multiple sclerosis, and though some agents have minor remyelinating potential, none adequately regenerate damaged myelin sheaths. Thus, we believe in the importance of promoting remyelination as a therapeutic target. We suggest that use of exosomes to stimulate remyelination would be beneficial to multiple sclerosis patients.

Exosomes are small, 30–120 nm diameter membrane vesicles that are secreted by many cell types, and are involved in a multitude of functions, both physiological and pathological [3]. Inward budding of the late endosome leads to the formation of vesicle-containing multivesicular bodies, which then fuse with the plasma membrane to release exosomes. Exosomes do not contain a random sampling of their parent cell's cytoplasm, rather, their specific composition is influenced by disease and/or activation state. Exosomes have the potential for targeting specific cell types to deliver their cargo of protein, mRNA and importantly, miRNA. miRNA are small non-coding RNA molecules that are increasingly recognized for their role in regulating gene expression. A new Common Fund initiative from the NIH Director's Office is designed, in part, to test the clinical utility of extracellular RNA for the development of novel therapeutics.

There has been significant interest in exploiting these naturally formed vesicles by re-engineering them as specific immunomodulators, or delivery platforms for the development of cancer therapeutics [4] and vaccines [5]. However, much of the current research on exosomes, in the context of multiple sclerosis, has focused on the utility of extracellular miRNAs as prognostic and/or diagnostic biomarkers. While promising, this is an arduous process, with 122 miRNAs currently identified as exclusively associated with multiple sclerosis [6]. Further refinement to determine which subset of these miRNAs are best suited to serve as biomarkers is a valuable pursuit. Nonetheless, we believe that exosomes have great potential not only as multiple sclerosis biomarkers, but for therapeutic purposes as well.

Though, as mentioned above, no current multiple sclerosis therapeutic adequately restores myelin, environmental enrichment is a most opportune means of improving recovery. It is well documented that exposure to environmental enrichment improves outcomes of brain

trauma and neurodegenerative disorders, including demyelinating diseases such as multiple sclerosis [7]. Environmental enrichment consists of volitionally increased intellectual (i.e., learning and memory), physical and social activity. When sufficiently robust and followed by adequate periods of rest, these activities stimulate subsequent nutritive adaptation [8,9]. Importantly, environmental enrichment can enhance memory, and increase production of myelin at all ages [10]. We believe that a better understanding of the signaling involved in environmental enrichment-based neuroprotection will allow production of effective mimetics.

In a recent study, we discovered that serum exosomes produced by young or environmental enrichment-exposed rats significantly increased myelin content, oligodendrocyte precursor cell and neural stem cell levels, and reduced oxidative stress in hippocampal slice cultures and when nasally administered to naive rats [11]. These exosomes also improved recovery from lyssolecithin-induced demyelination in slice culture, an *in vitro* model of multiple sclerosis. Importantly, we found that exposure of aged animals to environmental enrichment restored their ability to produce these myelination-promoting exosomes. These serum exosomes contain high levels of miR-219, which plays a role in oligodendrocyte maturation and the formation and maintenance of compact myelin [12,13]. miR-219 is necessary and sufficient for oligodendrocyte precursor cell differentiation [14], and is deficient in human multiple sclerosis lesions [15]. These data led to a second project using bone marrow-derived dendritic cell cultures as a scalable, exogenous source for production of similarly pro-myelinating exosomes [16].

To mimic environmental enrichment, we stimulated primary dendritic cell cultures with low-level IFN- $\gamma$ , a proinflammatory cytokine that is phasically increased during environmental enrichment. Though its role in multiple sclerosis is contested and largely thought to be detrimental, we have recently shown that phasic stimulation with low-level IFN- $\gamma$  significantly increased myelination in cultured brain slices or when administered nasally to animals. We found that exosomes produced by IFN- $\gamma$ -stimulated dendritic cells increased myelination and oxidative tolerance *in vitro* and *in vivo*. Like their serum-derived predecessors, these IFN- $\gamma$ -stimulated dendritic cell-derived exosomes also contain high levels of miR-219, increase oligodendrocyte precursor differentiation and improve recovery from acute experimental demyelination. Additionally, IFN- $\gamma$ -stimulated dendritic cell-derived exosomes are preferentially taken up by oligodendrocytes, suggesting they directly stimulate these cells.

This work is a first step in proof-of-principal work. However, it shows for the first time that it is feasible to use cells from donors to generate exosomes that effectively remyelinate brain, without adversely impacting endogenous neural stem cells. We suggest that advancement of dendritic cell exosomes as a remyelination therapy may include re-engineering them to contain desired miRNAs, and optimizing *in vivo* targeting methods to direct exosomes to specific cells.

We propose that adjunct use of these exosomes to stimulate remyelination would be beneficial to patients undergoing immunomodulatory therapy for multiple sclerosis. As demonstrated by work done with vaccine development, these exosomes may be additionally

altered to reduce inflammation as well. For example, stimulated dendritic cell exosomes contain high levels of specific anti-inflammatory miRNAs that may serve an immunomodulatory role in suppressing development of multiple sclerosis [16]. Indeed, work by the Whitacre group shows that serum exosomes are responsible for pregnancy-induced immunosuppression that ameliorates experimental autoimmune encephalitis, an animal model of multiple sclerosis [17]. Further examination of the immunomodulatory capacity of dendritic cell-derived exosomes, as well as optimization of their ability to stimulate remyelination and stem cell propagation/differentiation may lead to an even more effective therapeutic.

Additionally, it is important to stress that exosomes are non-toxic and can easily cross the blood–brain barrier without use of an additive vehicle [16]. Thus, in addition to the aforementioned positive attributes, exosomes are an ideal delivery platform. Taken together, this supports the importance of continued exosome research for their development as therapeutics for remyelination, and advocates their study for use in other neurodegenerative disorders as well.

## References

1. Kuhlmann T, Miron V, Cui Q, et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. *Brain*. 2008; 131(7):1749–58. [PubMed: 18515322]
2. Wiendl H, Toyka KV, Riekmann P, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG). Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. *J Neurol*. 2008; 255(10):1449–63. [PubMed: 19005625]
3. Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. *Int J Mol Sci*. 2013; 14(3):5338–66. [PubMed: 23466882]
4. Rountree RB, Mandl SJ, Nachtwey JM, et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. *Cancer Res*. 2011; 71(15):5235–44. [PubMed: 21670078]
5. Hartman ZC, Wei J, Glass OK, et al. Increasing vaccine potency through exosome antigen targeting. *Vaccine*. 2011; 29(50):9361–7. [PubMed: 22001882]
6. Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. *PLoS One*. 2009; 4(10):e7740. [PubMed: 19936230]
7. Magalon K, Cantarella C, Monti G, et al. Enriched environment promotes adult neural progenitor cell mobilization in mouse demyelination models. *Eur J Neurosci*. 2007; 25(3):761–71. [PubMed: 17298600]
8. Mattson MP, Duan W, Lee J, Guo Z. Suppression of brain aging and neurodegenerative disorders by dietary restriction and environmental enrichment: molecular mechanisms. *Mech Ageing Dev*. 2001; 122(7):757–78. [PubMed: 11322996]
9. Kraig RP, Mitchell HM, Christie-Pope B, et al. TNF- $\alpha$  and microglial hermetic involvement in neurological health & migraine. *Dose Response*. 2010; 8(4):389–413. [PubMed: 21191481]
10. Fields RD. White matter in learning, cognition and psychiatric disorders. *Trends Neurosci*. 2008; 31(7):361–70. [PubMed: 18538868]
11. Pusic AD, Kraig RP. Youth and environmental enrichment generate serum exosomes containing mir-219 that promote CNS myelination. *Glia*. 2014; 62:284–99. [PubMed: 24339157]
12. Dugas JC, Cuellar TL, Scholze A, et al. Dicer1 and miR-219 are required for normal oligodendrocyte differentiation and myelination. *Neuron*. 2010; 65(5):597–611. [PubMed: 20223197]

13. Zhao X, He X, Han X, et al. MicroRNA-mediated control of oligodendrocyte differentiation. *Neuron*. 2010; 65(5):612–26. [PubMed: 20223198]
14. Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. *Brain*. 2009; 132(12):3342–52. [PubMed: 19952055]
15. Shin D, Shin JY, McManus MT, et al. Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. *Ann Neurol*. 2009; 66(6):843–57. [PubMed: 20035504]
16. Pusic AD, Pusic KM, Kraig RP. IFN $\gamma$  Stimulated Dendritic Cell Exosomes as a Potential Therapeutic for Remyelination. *J Neuroinflammation*. 2014; 266(1–2):12–23.
17. Williams JL, Gatson NN, Smith KM, et al. Serum exosomes in pregnancy-associated immune modulation and neuroprotection during CNS autoimmunity. *Clin Immunol*. 2013; 149(2):236–43. [PubMed: 23706172]